Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Res. 2011 Nov 15;72(1):365–374. doi: 10.1158/0008-5472.CAN-11-1831

Figure 3. CD44 is associated with and contributes to increased OSCC aggressiveness.

Figure 3

A. FACS analysis of cell surface CD44 expression by pan-CD44 antibody (1M7) and isotype control shown for MOC1, 2 and 10. B. Representative mean fluorescence intensity for cell surface CD44 expression in all 6 cell lines (from one of at least three experiments). C. FACS analysis of cell surface CD44 expression in MOC10 after shRNA knockdown of CD44 with 3 distinct shRNAs (CD44-6, CD44-7, CD44-10) or scramble control shRNA (quantitated by indicated MFI). D. Scratch Test of MOC10 after transduction with indicated CD44 or scramble shRNAs. E. CD44 shRNA knockdown leads to delayed or abrogated growth of MOC10. MOC10 cells (1×104) transduced with scramble, CD44-7, or CD44-10 shRNA were injected into the right flank of C57BL/6 WT mice and monitored. Growth curves only represent average tumor diameter of transplanted tumors that grew out as indicated (***=p<0.001).